Clinical trial • Phase III • Endocrinology

survodutide for Overweight | Obesity

Phase III trial of survodutide for Overweight | Obesity. 56 participants.

Overview

Trial Therapeutic Area
Endocrinology
Trial Disease
Overweight | Obesity
Trial Stage
Phase III
Drug Modality
Peptide/protein/enzyme

Key dates

Initial CTIS Submission Date
26-11-2025
First CTIS Authorization Date
28-01-2026

Trial design

Phase III trial across 1 site in Germany.

Target Sample Size
56

Eligibility

Recruits 56 Vulnerable populations not selected; no specific consent or assent handling indicated..

Vulnerable Population
Vulnerable populations not selected; no specific consent or assent handling indicated.

Recruitment

Planned Sample Size
56
Recruitment Window Months
3

Geography

Total Number Of Sites
1
Total Number Of Participants
56

Germany

Earliest CTIS Part Ii Submission Date
16-01-2026
Latest Decision Or Authorization Date
28-01-2026
Processing Time Days
12
Number Of Sites
1
Number Of Participants
56

Sites

Site Name
Boehringer Ingelheim Pharma GmbH & Co. KG (address: Birkendorfer Strasse 65, Biberach An Der Riss, 88397)
Department Name
Global Clinical Development & Operations
Contact Person Name
Khaled Schneider

Sponsor

Primary sponsor

Full Name
Boehringer Ingelheim International GmbH
Organisation Type
Pharmaceutical company
Country Of Registered Address
Germany

Investigational products

Investigational Product Name
survodutide
Active Substance
survodutide
Modality
Peptide/protein/enzyme
Routes Of Administration
given in different ways, either as a pre-filled syringe or a pen-like injector

Related trials

Other published trials that may interest you.